Fig 1.
Flowchart.
Table 1.
2 × 2 contingency table for disproportionality analysis.
Table 2.
Methods of disproportionality analysis and signal detection criteria.
Table 3.
Clinical features of bowel cleansers associated cases.
Fig 2.
Clinical characteristics of patients.
(a) Age and gender distribution. (b) Outcomes of 75 reported cases. (c) Reporter classification. (d) Distribution by country.
Fig 3.
(a) Cases associated with all bowel cleansers. (b) Cases associated with bisacodyl. (c) Cases associated with PEG. (d) Cases associated with OSS. (e) Seasonal variation and Case Counts.
Table 4.
Disproportionality analysis.
Fig 4.
Top 10% PTs of bowel cleansers ranked by case frequency.
Table 5.
Clinical indications and outcomes by type of bowel cleanser.
Fig 5.
Distribution of adverse event outcomes.
(a) Outcomes of cases using bisacodyl. (b) Outcomes of cases using PEG. (c) Outcomes of cases using OSS. (d) Outcomes among female patients. (e) Outcomes among male patients.
Table 6.
Logistic regression analysis of ischemic colitis occurrence.
Table 7.
Logistic regression analysis of mortality and life-threatening outcomes.
Table 8.
Concomitant medications with bowel cleansers in total and severe outcome cases.